AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

Precision therapy with targeted agents against tyrosine kinases and cancer-associated
molecules has been leading the revolution of cancer treatment 1]–7]. Cancer immunotherapy represents another wave of revolution in cancer therapy 8]–13]. In addition to monoclonal antibodies against CD20 and CD30 14], 15], the main agents of immunotherapeutics in clinical development include the following
: (1) immunomodulators (e.g., lenalidomide) 16]; (2) immune checkpoint blockers (e.g., pembrolizumab, nivolumab, ipilumumab) 10], 11], 17]; (3) T cell activators (e.g., CAR-T19; blinatumomab, AFM11) 18]–20]; (4) inhibitors of B cell receptor signaling (e.g., ibrutinib) 2], 21]; and (5) NK cell activators (e.g., AFM13) 22]. AFM13 is a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK
cell-mediated immunotherapy.